JUN and breast cancer: In summary, our results reveal that ISO treatment results in c-Jun phosphorylation/activation, and the activated c-Jun binds to the miR-137 promoter region, resulting in the promotion of miR-137 transcription, which consequently inhibits GSK3β and HSP70 protein translation, MMP-2 mRNA stability, and BC invasion.